Results 121 to 130 of about 48,073 (302)

Purification and characterization of the D2-dopamine receptor from bovine anterior pituitary.

open access: hybrid, 1988
Susan E. Senogles   +3 more
openalex   +1 more source

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

open access: yesBritish Journal of Pharmacology, EarlyView.
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander   +5 more
wiley   +1 more source

Targeting dopamine receptor D2 as a novel therapeutic strategy in endometrial cancer. [PDF]

open access: yesJ Exp Clin Cancer Res, 2021
Pierce SR   +19 more
europepmc   +1 more source

Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT2A receptor agonists

open access: yesBritish Journal of Pharmacology, EarlyView.
Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture movements and a perceived concern about harm through recreational use, and their consequent legal prohibition in the early 1970s.
Trevor Sharp, Aurelija Ippolito
wiley   +1 more source

D2-like dopamine receptors mediate the response to amphetamine in a mouse model of ADHD

open access: yesNeurobiology of Disease, 2007
The mechanisms underlying the effects of psychostimulants in attention deficit hyperactivity disorder (ADHD) are not well understood, but indirect evidence implicates D2 dopamine receptors. Here we dissect the components of dopaminergic neurotransmission
Xueliang Fan, Ellen J. Hess
doaj  

Dopamine D3 receptor blockade accelerates the extinction of opioid withdrawal‐induced drug‐seeking behaviours and alters microglia in dopaminoceptive nuclei

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose Among all drugs of abuse, opioids cause most of the deaths and treatment seeking. Despite abundant research in multifaceted therapeutic strategies, a high rate of relapse still characterises this condition. Dopamine D3 receptor antagonists combined with cue‐exposure therapies have been proposed to ameliorate the abused drugs ...
Aurelio Franco‐García   +3 more
wiley   +1 more source

Epidermal growth factor receptor as a molecular determinant of glioblastoma response to dopamine receptor D2 inhibitors. [PDF]

open access: yesNeuro Oncol, 2021
He Y   +9 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy